In-situ immune markers predict nivolumab (N) plus /-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial

被引：2
|
作者：
Meylan, M.
Sun, C-M.
Elaidi, R-T.
Moreira, M.
Bougouin, A.
Verkarre, V.
Bennamoun, M.
Chevreau, C. M.
Borchiellini, D.
Barthelemy, P.
Pannier, D.
Maillet, D.
Goupil, M. Gross
Tournigand, C.
Braychenko, E.
Phan, L.
Oudard, S.
Fridman, W-H.
Sautes-Fridman, C.
Vano, Y-A.
机构：
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1451MO
引用
收藏
页码：S1207 / S1207
页数：1
相关论文
共 50 条
  • [1] The influence of body composition on the survival of patients with metastatic clear cell renal carcinoma (mccRCC) treated with nivolumab (nivo) plus ipilimumab (ipi).
    Grewal, Kabir
    Chauhan, Pankaj Kumar
    Mukhida, Sagar S.
    Tannir, Nizar M.
    Venkatesh, Neha
    Shah, Amishi Yogesh
    Zurita, Amado J.
    Johns, Andrew
    Campbell, Matthew T.
    Goswami, Sangeeta
    Gao, Jianjun
    Jonasch, Eric
    Mcquade, Jennifer Leigh
    Alhalabi, Omar
    Msaouel, Pavlos
    Hahn, Andrew Warren
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 545 - 545
  • [2] Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma
    Moussa, Mohammad Jad
    Khandelwal, Jaanki
    Wilson, Nathaniel R.
    Malikayil, Kiran L.
    Surasi, Devaki Shilpa
    Bathala, Tharakeswara K.
    Lin, Yiyun
    Rao, Priya
    Tamboli, Pheroze
    Sircar, Kanishka
    Ajufo, Helen
    Elsayes, Khaled M.
    Shah, Amishi
    Johns, Andrew C.
    Goswami, Sangeeta
    Hasanov, Elshad
    Jonasch, Eric
    Msaouel, Pavlos
    Campbell, Matthew T.
    Alhalabi, Omar
    Tannir, Nizar M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (02)
  • [3] Intratumoral T-cell infiltration and response to nivolumab plus ipilimumab in patients with metastatic clear cell renal cell carcinoma from the CheckMate-214 trial
    Matar, Sayed
    Jegede, Opeyemi
    Denize, Thomas
    Ghandour, Fatme
    Laimon, Yasmin Nabil
    El Ahmar, Nourhan
    Sheshdeh, Aseman Bagheri
    Savla, Varunika
    Mohanna, Razan Assaad
    Catalano, Paul J.
    Braun, David A.
    Sun, Maxine
    Gupta, Saurabh
    Vemula, Sai Vikram
    Freeman, Gordon J.
    Motzer, Robert J.
    Atkins, Michael B.
    McDermott, David F.
    Choueiri, Toni K.
    Signoretti, Sabina
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
    Nazli Dizman
    Luis Meza
    Paulo Bergerot
    Marice Alcantara
    Tanya Dorff
    Yung Lyou
    Paul Frankel
    Yujie Cui
    Valerie Mira
    Marian Llamas
    Joann Hsu
    Zeynep Zengin
    Nicholas Salgia
    Sabrina Salgia
    Jasnoor Malhotra
    Neal Chawla
    Alex Chehrazi-Raffle
    Ramya Muddasani
    John Gillece
    Lauren Reining
    Jeff Trent
    Motomichi Takahashi
    Kentaro Oka
    Seiya Higashi
    Marcin Kortylewski
    Sarah K. Highlander
    Sumanta K. Pal
    Nature Medicine, 2022, 28 : 704 - 712
  • [5] Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
    Dizman, Nazli
    Meza, Luis
    Bergerot, Paulo
    Alcantara, Marice
    Dorff, Tanya
    Lyou, Yung
    Frankel, Paul
    Cui, Yujie
    Mira, Valerie
    Llamas, Marian
    Hsu, Joann
    Zengin, Zeynep
    Salgia, Nicholas
    Salgia, Sabrina
    Malhotra, Jasnoor
    Chawla, Neal
    Chehrazi-Raffle, Alex
    Muddasani, Ramya
    Gillece, John
    Reining, Lauren
    Trent, Jeff
    Takahashi, Motomichi
    Oka, Kentaro
    Higashi, Seiya
    Kortylewski, Marcin
    Highlander, Sarah K.
    Pal, Sumanta K.
    NATURE MEDICINE, 2022, 28 (04) : 704 - +
  • [6] Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N plus I) or sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Motzer, Robert J.
    Choueiri, Toni K.
    McDermott, David F.
    Powles, Thomas
    Yao, Jin
    Ammar, Ron
    Papillon-Cavanagh, Simon
    Saggi, Shruti S.
    McHenry, Brent M.
    Ross-Macdonald, Petra
    Wind-Rotolo, Megan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N plus I) and the primary tumour (PT) in place
    Meerveld-Eggink, A.
    Graafland, N.
    Wilgenhof, S.
    Van Thienen, J. V.
    Grant, M.
    Szabados, B. E.
    Abu-Ghanem, Y.
    Boleti, E.
    Blank, C. U.
    Haanen, J. B. A. G.
    Powles, T. B.
    Bex, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S575 - S575
  • [8] Efficacy of tyrosine kinase inhibitors (TKI) after combination ipilimumab plus nivolumab (I/N) in metastatic clear cell renal cell carcinoma (ccmRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).
    Kalirai, Austin
    Joy, Isaiah
    Ghosh, Sunita
    Kollmannsberger, Christian K.
    Hansen, Aaron Richard
    Thana, Myuran
    Graham, Jeffrey
    Heng, Daniel Yick Chin
    Castonguay, Vincent
    Bjarnason, Georg A.
    Breau, Rodney H.
    Kapoor, Anil
    Pouliot, Frederic
    Wood, Lori
    Basappa, Naveen S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [9] Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920.
    Tykodi, Scott S.
    Gordan, Lucio N.
    Alter, Robert S.
    Arrowsmith, Edward
    Harrison, Michael Roger
    Percent, Ivor John
    Singal, Rakesh
    Van Veldhuizen, Peter J.
    George, Daniel J.
    Hutson, Thomas E.
    Zhang, Joshua
    Zoco, Jesus
    Johansen, Jennifer L.
    Kalebasty, Arash Rezazadeh
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [10] Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.
    Ficial, Miriam
    Jegede, Opeyemi
    Sant'Angelo, Miriam
    Moreno, Sonia
    Braun, David A.
    Wind-Rotolo, Megan
    Pignon, Jean-Christophe
    Catalano, Paul J.
    Sun, Maxine
    Van Allen, Eliezer Mendel
    Freeman, Gordon J.
    Sharpe, Arlene
    Hodi, F. Stephen
    Motzer, Robert J.
    Wu, Catherine J.
    Atkins, Michael B.
    McDermott, David F.
    Shukla, Sachet A.
    Choueiri, Toni K.
    Signoretti, Sabina
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345